Dosage Forms Of Tafamidis And Its Pharmaceutically Acceptable Salt Thereof

Abstract: “Dosage forms of tafamidis and its pharmaceutically acceptable salt thereof” The disclosure relates to a novel liquid dosage form comprising composition containing tafamidis or its pharmaceutically acceptable salt particularly tafamidis meglumine and process of preparation thereof. The disclosure also relates to a novel liquid dosage form which is indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.

Patent Information

Applicants

Inventors

Specification

Documents

Application Documents